Mobile App

Google Play Apple Store
2024 Highlights and Hindsight in CLL: End of Year Updates
AMA/ABS/ANCC - Video
There have been multiple key advances in the treatment landscape of chronic lymphocytic leukemia (CLL) in 2024. To that end, a number of double and triple combination studies have been completed or are currently underway and, innovative therapies such as bispecific antibodies and chimeric antigen receptor (CAR) T cells are being developed for CLL. In Highlights and Hindsight in CLL, Dr. Matthew Davids describes the most significant ongoing studies and publications in CLL from 2024 and details their impact on the treatment continuum. This activity enables participants to stay updated on the most relevant breakthroughs and improve outcomes among patients.
Review the activity and claim AMA, ABS, or ANCC credit/contact hour after completion of a brief pretest and posttest/evaluation.



 
Matthew Davids, MD, MMSc Matthew Davids, MD, MMSc
Director of Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute

There have been multiple key advances in the treatment landscape of chronic lymphocytic leukemia (CLL) in 2024. To that end, a number of double and triple combination studies have been completed or are currently underway and, innovative therapies such as bispecific antibodies and chimeric antigen receptor (CAR) T cells are being developed for CLL. In Highlights and Hindsight in CLL, Dr. Matthew Davids describes the most significant ongoing studies and publications in CLL from 2024 and details their impact on the treatment continuum. This activity enables participants to stay updated on the most relevant breakthroughs and improve outcomes among patients.
Review the activity and claim AMA, ABS, or ANCC credit/contact hour after completion of a brief pretest and posttest/evaluation.





 
Matthew Davids, MD, MMSc Matthew Davids, MD, MMSc
Director of Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute

 

Thank you for completing this activity!


An email will be sent to you shortly with your certificate attached. If you do not receive this email within 30 minutes, please check your "Junk" or "Spam" folder. You can also visit your profile page for a list of downloadable certificates you've earned.

For your convenience you can download your certificate by clicking the button below.


If you have any questions or experience issues, please contact us.

20
Supported by an educational grant from
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Launch Date: December 16, 2024
Release Date: December 16, 2024
Expiration Date: November 30, 2025

Mini Module
7849
2024Highlights_CLL(1730x162).gif
True
  • Hematology
Hematology

CookieConsent

Change Settings